• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Alnylam Pharmaceuticals (NQ: ALNY )

    153.86 -3.44 (-2.19%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jun 18, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 587,748
    Open 157.30
    Bid (Size) 153.85 (10)
    Ask (Size) 153.96 (2)
    Prev. Close 157.30
    Today's Range 152.30 - 157.32
    52wk Range 141.97 - 218.88
    Shares Outstanding 118,847,693
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Here's How Much $1000 Invested In Alnylam Pharmaceuticals 5 Years Ago Would Be Worth Today
    Via Benzinga
    $100 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth This Much Today
    Via Benzinga

    Performance

    YTD
    -21.07%
    -21.07%
    1 Month
    +2.41%
    +2.41%
    3 Month
    +3.84%
    +3.84%
    6 Month
    -17.94%
    -17.94%
    1 Year
    -23.68%
    -23.68%

    More News

    Read More
    Behind the Scenes of Alnylam Pharmaceuticals's Latest Options Trends
    Via Benzinga
    June’s Biotech Boom: 3 Stocks to Buy for a Summertime Surge
    Via InvestorPlace
    (ALNY) - Analyzing Alnylam Pharmaceuticals's Short Interest
    Via Benzinga
    10 Health Care Stocks With Whale Alerts In Today's Session
    Via Benzinga
    How Is The Market Feeling About Alnylam Pharmaceuticals?
    Via Benzinga
    Alnylam Issues 2023 Corporate Responsibility Report
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    ALNY Stock Earnings: Alnylam Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024
    Via InvestorPlace
    Alnylam Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Period Activity
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    Alnylam to Webcast Conference Call Discussing First Quarter 2024 Financial Results
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    10 Health Care Stocks With Whale Alerts In Today's Session
    Via Benzinga
    Analysts Express Confidence in Alnylam's Hypertension Drug Despite Mixed Trial Data
    Via Benzinga
    Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    $100 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth This Much Today
    Via Benzinga
    Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback
    Via Investor's Business Daily
    Exposures Product Safety
    3 Biotech Stocks to Buy on the Dip: March 2024
    Via InvestorPlace
    Alnylam to Webcast Investor Event to Discuss Results from KARDIA-2 Phase 2 Study of Zilebesiran at American College of Cardiology Scientific Session
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 15 Years
    Via Benzinga
    Billionaire’s Biotech Bets: 3 Stocks Dominating Bill Gates’ Portfolio
    Via InvestorPlace
    Alnylam Launches Hereditary ATTR (hATTR) Amyloidosis Campaign to Help Shorten Time to Diagnosis for Inherited and Rapidly Progressive Disease
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    Pharma Stock Roundup: Novo Nordisk's New Obesity Pill Data, Roche, AstraZeneca's Pipeline Updates
    Via Talk Markets
    Exposures Product Safety
    Roche/Alnylam Blood Pressure Drug Aces In Mid-Stage Trial, Analyst Says Zilebesiran As Promising Opportunity In Addressing Global Hypertension Challenges
    Via Benzinga
    Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran is Added to Standard of Care Antihypertensives
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    10 Health Care Stocks Whale Activity In Today's Session
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.